Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance

Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance After Multiple Oral Dosing of LY2623091 in Healthy Volunteers

The purpose of this study is to investigate the safety and tolerability of LY2623091 after multiple oral dosing in healthy men and women of non-childbearing potential. Two cohorts of 16 subjects will participate in 2 dosing periods. Treatment assignment will be double-blind for LY2623091 and placebo (negative control), and open label for eplerenone (positive control).

Study Overview

• Status: Completed
• Conditions: Chronic Kidney Disease
• Intervention / Treatment: Drug: Placebo; Drug: LY2623091; Drug: Eplerenone

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Zuidlaren, Netherlands, 9471 GP
    • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Are healthy men and women of non-childbearing potential as determined by medical history and physical examination.

  • Male subjects: Non-vasectomized male subjects must agree to use 2 medically accepted methods of contraception with all sexual partners during the study and for 90 days following the final dosing.
  • Female subjects: Female subjects must be of non-childbearing potential due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation) or menopause. They should be a minimum of 12 months without a menstrual period. Peri-menopausal women who are 6 months without a menstrual period.
• Have given written informed consent prior to any study-specific procedures.
• Are reliable and willing to make themselves available for the duration of the study and are willing to follow site-specific study procedures.
• Have a body mass index (BMI) of between 19 and 32.5 kilograms per square meter (kg/m^2).
• Have clinical laboratory test results within the normal reference range for the population or study site, or test results with acceptable deviations that are judged by the Investigator not to be clinically significant.
• Have venous access sufficient to allow blood sampling per the protocol.
• Have serum potassium levels within the normal range.
• Are nonsmokers or smokers of less than or equal to 10 cigarettes per day.

Exclusion Criteria:

• Are currently enrolled in, or have discontinued, within 60 days inclusive, a clinical trial involving an investigational drug, device or an off-label use of an approved drug, or are concurrently enrolled in any other type of medical research judged to be scientifically or medically incompatible with this study. Subjects who meet any of these criteria may be enrolled in this study but they cannot be dosed until at least 60 days following the last day of the previous investigational trial.
• Have previously completed or withdrawn from this study or any other study investigating LY2623091.
• Have a history or presence of medical illness including but not limited to any cardiovascular, hepatic, respiratory, hematological, endocrine or neurological disease, or any clinically significant laboratory abnormality that is of a serious medical problem that would preclude study participation.
• Have an abnormality in the 12-lead electrocardiogram (ECG), which increases the risks associated with participation in the study.
• Are unwilling or unable to comply with the use of an electronic data capture system.
• Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody or hepatitis B and/or positive hepatitis B surface antigen.

• Use and/or intend to use any medication for a medical condition that is not compatible with Inclusion Criterion. For medications that may be used in "healthy" subjects (example given: preventative and/or naturopathic agents, temporary symptom-relieving medications, and so forth) the following constraints must be observed:

  • No use of vasoactive drugs (example given: diuretics, antihypertensive agents, phosphodiesterase inhibitors, erectile dysfunction medications, nasal decongestants, et cetera) or systemic glucocorticoids within 7 days of first dosing and/or anticipated use during the study.
  • No use of acetaminophen/paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) within 24 hours of first dosing and/or anticipated use during the study. Aspirin may not be used at doses greater than 100 milligrams per day (mg/day) within 7days of first dosing and/or anticipated use during the study.
  • No use of herbal or nutritional products within 7 days of first dosing and/or anticipated use during the study.
• Have donated blood of more than 50 milliliters (mL) within the last 60 days.
• Have an average weekly alcohol intake that exceeds 21 units per week and/or subjects unwilling to stop alcohol within 48 hours of study enrollment and for the duration of the study.
• Have an abnormally high blood pressure (supine or standing) defined as diastolic blood pressure greater than 95 millimeters of mercury (mmHg) and /or systolic blood pressure greater than 150 mmHg, confirmed by at least 1 repeat measurement.
• Have serum potassium greater than the upper limit of normal.
• Regularly use known drugs of abuse or show positive findings for such use on urinary drug screening.
• Consumption of natural licorice and/or natural licorice-containing products and/or grapefruit and/or grapefruit juice within 7 days of first dosing and/or anticipated consumption during the study.
• Consumption of methylxanthine-containing beverages and/or foods (example: coffee, tea, caffeinated soft drinks, chocolate) within 4 days of first dosing and/or anticipated consumption during the study.
• Are unwilling to abstain from salt-substitutes containing potassium for the duration of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: DOUBLE

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: 1 mg LY2623091; Daily by mouth for 7 days.	Drug: LY2623091; Administered orally.
EXPERIMENTAL: 10 mg LY2623091; Daily by mouth for 7 days.	Drug: LY2623091; Administered orally.
EXPERIMENTAL: 25 mg LY2623091; The anticipated dose of LY2623091 was revised down from the original proposed dose level of 100 mg based on safety and tolerability data. The 25 mg LY2623091 was administered daily by mouth for 7 days.	Drug: LY2623091; Administered orally.
EXPERIMENTAL: 0.3 mg LY2623091; The anticipated dose of LY2623091 was revised down from the original proposed dose level of up to 200 mg. The 0.3 mg LY2623091 was determined based on an interim analysis after the third dose level and was administered daily by mouth for 7 days.	Drug: LY2623091; Administered orally.
PLACEBO_COMPARATOR: Placebo; Daily by mouth for 7 days.	Drug: Placebo; Administered orally.
ACTIVE_COMPARATOR: 50 mg Eplerenone; Daily by mouth for 7 days.	Drug: Eplerenone; Administered orally.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Clinically Significant Effects (Adverse Events)	A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.	Baseline through 7 days for each treatment period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacodynamics: Serum to Urine Potassium Area Under the Concentration-Time Curve (AUC) Standardized for Urinary Excretion at Day 7	A measure of the renal clearance of the potassium ion (K+). The Least Squares (LS) Mean value was adjusted for pre-challenge renal K+ clearance.	Day 7: 24 Hour (hr), 48hr and 72hr Postdose
Pharmacokinetics of LY2623091: Maximal Concentration (Cmax) at Day 6	Cmax estimated for LY2623091.	Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose
Pharmacokinetics LY2623091: Area Under the Concentration-Time Curve (AUC) at Day 6	AUC from time 0, extrapolated to infinity, estimated for LY2623091.	Day 6: Predose,1hr, 2hr, 3hr, 4hr, 8hr and 12 hr Postdose

Collaborators and Investigators

• Sponsor: Eli Lilly and Company

Study record dates

Study Major Dates

• Study Start: October 1, 2010
• Primary Completion (ACTUAL): January 1, 2011
• Study Completion (ACTUAL): January 1, 2011

Study Registration Dates

• First Submitted: November 8, 2010
• First Submitted That Met QC Criteria: November 9, 2010
• First Posted (ESTIMATE): November 10, 2010

Study Record Updates

• Last Update Posted (ACTUAL): June 3, 2019
• Last Update Submitted That Met QC Criteria: February 15, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Keywords: Kidney; Renal
• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic; Physiological Effects of Drugs; Antihypertensive Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Natriuretic Agents; Diuretics; Hormone Antagonists; Mineralocorticoid Receptor Antagonists; Diuretics, Potassium Sparing; Eplerenone
• Other Study ID Numbers: 14121; I4M-MC-MRAB (OTHER: Eli Lilly)